임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 2상모집 중· HER2-positive Metastatic Breast CancerHER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
협력: 로슈
- 2상모집 중· Chronic Lymphocytic Leukemia (CLL)Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
리드: 아스트라제네카 · 협력: 애브비, 로슈
- 2상모집 중· Rheumatoid ArthritisAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
리드: 로슈
- 2상모집 중· Metastatic Castration-Resistant Prostate CancerA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
리드: 로슈
- 2상모집 중· Chronic Obstructive Pulmonary Disease (COPD)Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
협력: 로슈
- 2상모집 중· Acute Ischemic Stroke From Large Vessel OcclusionIntra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy
협력: 로슈
- 2상모집 중· Acute Respiratory Distress Syndrome (ARDS)JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
협력: 로슈
- 2상모집 중· Acute Respiratory Distress Syndrome (ARDS)JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
협력: 로슈
- 2상모집 중· Stage I Colon CancerPhase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
협력: 로슈
- 2상모집 중· Acute Respiratory Distress Syndrome (ARDS)JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
협력: 로슈
- 2상모집 중· Acute Respiratory Distress Syndrome (ARDS)JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
협력: 로슈
- 2상모집 중· Food HypersensitivityOmalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels
협력: 로슈
- 2상모집 중· Colorectal Carcinoma Metastatic in the LiverY-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
협력: 로슈
- 2상모집 중· Lymphoma, Mantle-CellPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
협력: 로슈
- 2상모집 중· Diffuse Large B Cell Lymphoma (DLBCL)A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
협력: 로슈
- 2상모집 중· Muscle-invasive Urothelial CarcinomaA Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
리드: 로슈 · 협력: 바이오엔테크
- 2상모집 중· Extranodal Marginal Zone LymphomaMosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
협력: 로슈
- 2상모집 중· Hairy Cell LeukemiaA Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
협력: 로슈
- 2상모집 중· Large B-cell LymphomaA Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
협력: 로슈
- 2상모집 중· Extensive-stage Small-cell Lung CancerStudy of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
협력: 로슈
- 2상모집 중· Metastatic Breast CancerSOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
협력: 로슈
- 2상모집 중· Metastatic Breast CancerNOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
협력: 로슈
- 2상모집 중· Mantle Cell LymphomaGlofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
협력: 일라이 릴리, 로슈
- 2상모집 중· Esophageal CancerA Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
협력: 머크(MSD), 로슈
- 2상모집 중· Chronic Lymphocytic LeukemiaPhase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
협력: 일라이 릴리, 로슈
- 2상모집 중· Adenocarcinoma, Pancreatic DuctalA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
리드: 로슈 · 협력: 바이오엔테크
- 2상모집 중· Lymphoma, FollicularMosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
협력: 로슈
- 2상모집 중· Diffuse Large B-Cell LymphomaTesting Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
협력: 로슈
- 2상모집 중· Platinum-Resistant Fallopian Tube CarcinomaVismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
협력: 로슈
- 2상모집 중· Geographic AtrophyA Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
리드: 로슈
- 2상모집 중· Squamous Cell Carcinoma of the Anal CanalTiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
협력: 로슈
- 2상모집 중· Refractory Non-Hodgkin LymphomaCAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
협력: 로슈
- 2상모집 중· Locally Advanced Hepatocellular CarcinomaMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
협력: 로슈
- 2상모집 중· Follicular LymphomaMosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
협력: 로슈
- 2상모집 중· Small Cell Neuroendocrine Carcinoma of BladderAtezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
협력: 로슈
- 2상모집 중· Locally Advanced Hepatocellular CarcinomaAtezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
협력: 로슈
- 2상모집 중· Chronic Lymphocytic Leukemia (CLL)Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
리드: 애브비 · 협력: 로슈
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.